Drug Trial Radar · NCT06590857
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Jul 19, 2024
Primary completion
Oct 2028
Study completion Nov 2033
Sponsor
- Lead sponsor
- RayzeBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
Conditions
- Metastatic Breast Cancer
- HER2-negative Breast Cancer
- ER+ Breast Cancer
- Advanced Breast Cancer
- Metastatic Breast Cancer With Bone Involvement
- Bone Metastases in Subjects With Advanced Breast Cancer
- ER-Positive HER2-Negative Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- Hormone-sensitive Metastatic Breast Cancer
- Hormone-Sensitive Breast Cancer
Interventions
RYZ101Drug
Ac-225
Standard of Care Endocrine TherapyDrug
Investigator's choice of endocrine therapy, such as, anastrozole, elacestrant, exemestane, fulvestrant, imlunestrant, letrozole, tamoxifen, or vepdegestrant
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose EscalationTime frame: 6 weeks of RYZ101 treatment
- Endocrine Therapy Combination Dose EscalationTime frame: [Time Frame: 6 weeks of study treatment]
- Endocrine Therapy Combination Dose EscalationTime frame: Up to approximately 5 years after the last subject has completed RYZ101 treatment
- Endocrine Therapy Combination Dose Escalation and ExpansionTime frame: Up to approximately 5 years after the last subject has completed RYZ101 treatment
- Endocrine Therapy Combination Dose Escalation and ExpansionTime frame: Up to approximately 5 years after the last subject has completed RYZ101 treatment
Locations
32 sites in 3 countries. Site status is shown where the registry gives one.
Research Facility
Phoenix, Arizona · Not yet recruiting
Research Facility
Irvine, California · Not yet recruiting
Research Facility
San Diego, California · Not yet recruiting
Research Facility
Santa Monica, California · Recruiting
Research Facility
Longmont, Colorado · Recruiting
Research Facility
Jacksonville, Florida · Not yet recruiting
Research Facility
Atlanta, Georgia · Not yet recruiting
Research Facility
Indianapolis, Indiana · Recruiting
Research Facility
Boston, Massachusetts · Not yet recruiting
Research Facility
Detroit, Michigan · Not yet recruiting
Research Facility
Maplewood, Minnesota · Not yet recruiting
Research Facility
Rochester, Minnesota · Not yet recruiting
Research Facility
St Louis, Missouri · Not yet recruiting
Research Facility
Omaha, Nebraska · Recruiting
Research Facility
Albuquerque, New Mexico · Not yet recruiting
Research Facility
Buffalo, New York · Not yet recruiting
Research Facility
New York, New York · Not yet recruiting
Research Facility
New York, New York · Not yet recruiting
Research Facility
Cleveland, Ohio · Not yet recruiting
Research Facility
Philadelphia, Pennsylvania · Not yet recruiting
Research Facility
Pittsburgh, Pennsylvania · Not yet recruiting
Research Facility
Dallas, Texas · Not yet recruiting
Research Facility
Houston, Texas · Not yet recruiting
Research Facility
Salt Lake City, Utah · Not yet recruiting
Research Facility
Norfolk, Virginia · Not yet recruiting
Research Facility
Seattle, Washington · Recruiting
Research Facility
Vancouver, British Columbia, Canada · Recruiting
Research Facility
Toronto, Ontario, Canada · Not yet recruiting
Research Facility
Toronto, Ontario, Canada · Not yet recruiting
Research Facility
Québec, Quebec, Canada · Not yet recruiting
Research Facility
Seoul, Seoul, South Korea · Active not recruiting
Research Facility
Seoul, Seoul, South Korea · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.